

Anna Spreafico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3848598/publications.pdf>

Version: 2024-02-01

162
papers

4,785
citations

168829

31
h-index

124990

64
g-index

163
all docs

163
docs citations

163
times ranked

8305
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , 2022, 128, 497-508.	2.0	4
2	Treatment outcomes and survival following definitive (chemo)radiotherapy in <scp>HPV</scp>-positive oropharynx cancer: Large-scale comparison of <scp>DAHANCA</scp> vs <scp>PMH</scp> cohorts. <i>International Journal of Cancer</i> , 2022, 150, 1329-1340.	2.3	8
3	Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytab478.	0.3	8
4	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	3.5	9
5	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, , .	1.2	1
6	Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center. <i>JCO Oncology Practice</i> , 2022, , OP2100810.	1.4	1
7	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. <i>Cancers</i> , 2022, 14, 89.	1.7	5
8	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	1.7	3
9	Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2550-2550.	0.8	2
10	Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2528-2528.	0.8	3
11	Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2546.	0.8	13
12	Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2500-2500.	0.8	17
13	Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody-drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3154-TPS3154.	0.8	0
14	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
15	The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2589-2589.	0.8	2
16	External validation of the VIGex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2510-2510.	0.8	1
17	Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9579-9579.	0.8	5
18	Phase Ib study of anetumab ravtansiv in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4136-4136.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Prognostic factors in sinonasal cancers: A multicenter pooled analysis.. Journal of Clinical Oncology, 2022, 40, 6092-6092.	0.8	0
20	Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.. Journal of Clinical Oncology, 2022, 40, e21575-e21575.	0.8	0
21	Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2022, 40, e18630-e18630.	0.8	0
22	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 460-472.	3.2	48
23	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. Cancer Treatment Reviews, 2021, 92, 102125.	3.4	15
24	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. Laryngoscope, 2021, 131, E1162-E1171.	1.1	9
25	Short-term and long-term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	0.9	1
26	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. Radiotherapy and Oncology, 2021, 156, 95-101.	0.3	2
27	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiotherapy and Oncology, 2021, 154, 70-75.	0.3	23
28	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. JNCI Cancer Spectrum, 2021, 5, pkaa122.	1.4	12
29	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
30	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. Journal of the National Cancer Institute, 2021, 113, 980-988.	3.0	25
31	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. Oral Oncology, 2021, 114, 105167.	0.8	11
32	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). British Journal of Cancer, 2021, 124, 1543-1551.	2.9	19
33	Importance of Margins, Radiotherapy, and Systemic Therapy in Mucosal Melanoma of the Head and Neck. Laryngoscope, 2021, 131, 2269-2276.	1.1	9
34	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. Radiotherapy and Oncology, 2021, 157, 255-262.	0.3	4
35	The Future of Clinical Trial Design in Oncology. Cancer Discovery, 2021, 11, 822-837.	7.7	32
36	Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).. Journal of Clinical Oncology, 2021, 39, 2640-2640.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Prospective manipulation of the gut microbiome with Microbial Ecosystem Therapeutic 4 (MET4) in locoregionally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation (ROMA2).. Journal of Clinical Oncology, 2021, 39, 6059-6059.	0.8	1
38	Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.. Journal of Clinical Oncology, 2021, 39, 6081-6081.	0.8	3
39	Outcomes of non-treatment naïve melanoma patients with central nervous system relapse.. Journal of Clinical Oncology, 2021, 39, 9557-9557.	0.8	0
40	BRAF testing timelines and impact on the starting of systemic treatment.. Journal of Clinical Oncology, 2021, 39, e21575-e21575.	0.8	1
41	Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.. Journal of Clinical Oncology, 2021, 39, TPS2679-TPS2679.	0.8	0
42	Patient experience of early high grade symptomatic adverse events on early phase clinical trials using the PRO-CTCAE.. Journal of Clinical Oncology, 2021, 39, 12051-12051.	0.8	0
43	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology, 2021, 39, 9504-9504.	0.8	23
44	Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 3089-3089.	0.8	1
45	A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).. Journal of Clinical Oncology, 2021, 39, 11522-11522.	0.8	4
46	ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2513-2513.	0.8	7
47	Phase Ib study of the anti-TGF- β 2 monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2509-2509.	0.8	10
48	Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).. Journal of Clinical Oncology, 2021, 39, e15038-e15038.	0.8	2
49	Mega- and meta-analyses of fecal metagenomic studies in predicting response to immune checkpoint inhibitors.. Journal of Clinical Oncology, 2021, 39, 2570-2570.	0.8	0
50	Tumor-Na $\tilde{\nu}$ e Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4230-4244.	3.2	53
51	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 2021, 28, 2173-2179.	0.9	14
52	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS ONE, 2021, 16, e0253070.	1.1	17
53	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 334-341.	1.0	9
54	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers, 2021, 13, 3640.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	5.8	63
56	Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing. <i>MSystems</i> , 2021, 6, e0055221.	1.7	5
57	The Potential Impact and Usability of the Eighth Edition TNM Staging Classification in Oral Cavity Cancer. <i>Clinical Oncology</i> , 2021, 33, e442-e449.	0.6	5
58	Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-Like Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2470-2479.	0.3	1
59	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
60	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	1.4	14
61	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.3	22
62	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	1.1	5
63	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 469-472.	1.1	0
64	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.3	30
65	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26
66	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	5.7	253
67	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
68	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	1.5	23
69	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	2.0	31
70	Increasing operational and scientific efficiency in clinical trials. <i>British Journal of Cancer</i> , 2020, 123, 1207-1208.	2.9	11
71	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	1.1	7
72	Patient Selection Strategies to Maximize Therapeutic Index of Antibody-Drug Conjugates: Prior Approaches and Future Directions. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1770-1783.	1.9	10

#	ARTICLE	IF	CITATIONS
73	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	2.0	42
74	Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. <i>Oral Oncology</i> , 2020, 110, 104845.	0.8	17
75	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	1.3	21
76	Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. <i>Genome Medicine</i> , 2020, 12, 38.	3.6	9
77	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	0.8	8
78	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	0.8	6
79	347...Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. , 2020, , .		0
80	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	1.3	14
81	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6709-6720.	3.2	32
82	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e89.	1.8	4
83	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	1.4	4
84	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). , 2019, 7, 72.		38
85	Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI-853520. <i>Targeted Oncology</i> , 2019, 14, 67-74.	1.7	7
86	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 10-16.	0.3	8
87	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	2.0	94
88	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	2.0	115
89	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019, 24, e518-e525.	1.9	1
90	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	1.9	23

#	ARTICLE	IF	CITATIONS
91	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 363-373.	0.4	38
92	Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2019, 37, 1086-1086.	0.8	2
93	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.. Journal of Clinical Oncology, 2019, 37, 2507-2507.	0.8	113
94	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. Journal of Clinical Oncology, 2019, 37, 2542-2542.	0.8	5
95	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).. Journal of Clinical Oncology, 2019, 37, 6045-6045.	0.8	5
96	Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients.. Journal of Clinical Oncology, 2019, 37, 6047-6047.	0.8	3
97	Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).. Journal of Clinical Oncology, 2019, 37, TPS2664-TPS2664.	0.8	0
98	Abstract CT124: Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW). , 2019, , .		1
99	Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma. , 2019, , .		0
100	Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. , 2019, , .		0
101	Abstract CT190: A Phase II basket study of hypomethylating agent oral cc-486 and durvalumab in advanced solid tumors (METADUR). , 2019, , .		0
102	A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investigational New Drugs, 2018, 36, 1026-1036.	1.2	35
103	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer, 2018, 18, 136.	1.1	13
104	First-in-class human trial of the PI3K β -selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer, 2018, 124, 315-324.	2.0	29
105	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anti-Cancer Drugs, 2018, 29, 827-838.	0.7	9
106	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature, 2018, 563, 579-583.	13.7	624
107	A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. Journal of Clinical Oncology, 2018, 36, 2586-2586.	0.8	14
108	Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.. Journal of Clinical Oncology, 2018, 36, 3063-3063.	0.8	4

#	ARTICLE	IF	CITATIONS
109	Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.. Journal of Clinical Oncology, 2018, 36, e14559-e14559.	0.8	1
110	Patient knowledge, attitudes, and expectations of cancer immunotherapies.. Journal of Clinical Oncology, 2018, 36, e18551-e18551.	0.8	3
111	A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS2602-TPS2602.	0.8	4
112	Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).. Journal of Clinical Oncology, 2018, 36, 184-184.	0.8	0
113	Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants.. Journal of Clinical Oncology, 2018, 36, 6048-6048.	0.8	1
114	Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiology, 2017, 47, 28-34.	0.8	14
115	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1257-1265.	1.1	25
116	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. Current Treatment Options in Oncology, 2017, 18, 39.	1.3	9
117	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer. Cancer Discovery, 2017, 7, 610-619.	7.7	194
118	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 368.	1.2	19
119	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. Radiotherapy and Oncology, 2017, 124, 225-231.	0.3	33
120	Outcome following radiotherapy for head and neck basal cell carcinoma with "aggressive" features. Oral Oncology, 2017, 72, 157-164.	0.8	15
121	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Investigational New Drugs, 2017, 35, 11-25.	1.2	15
122	Validation of the Princess Margaret immune oncology prognostic index (PM-IPI) for patients (pts) treated in immune oncology (IO) early phase trials.. Journal of Clinical Oncology, 2017, 35, 3070-3070.	0.8	0
123	A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).. Journal of Clinical Oncology, 2017, 35, 11607-11607.	0.8	0
124	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Investigational New Drugs, 2016, 34, 575-583.	1.2	9
125	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2016, 67, 174-182.	1.3	75
126	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF</i> -mutant colorectal cancer (<i>BRAF</i> _m CRC).. Journal of Clinical Oncology, 2016, 34, 3544-3544.	0.8	79

#	ARTICLE	IF	CITATIONS
127	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 50290-50301.	0.8	27
128	Development of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI): A novel prognostic score for patients (pts) treated in immune oncology (IO) phase I (P1) trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3058-3058.	0.8	0
129	Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2578-2578.	0.8	0
130	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. <i>Frontiers in Pharmacology</i> , 2015, 6, 120.	1.6	21
131	Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the \pm -specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. <i>Cancer Research</i> , 2015, 75, CT136-CT136.	0.4	4
132	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2564-2564.	0.8	5
133	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated ($\hat{\alpha}$) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6020-6020.	0.8	7
134	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. <i>Oncotarget</i> , 2015, 6, 34561-34572.	0.8	10
135	Developing a CAncer genomics Digital Educational Tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6524-6524.	0.8	0
136	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073.	2.0	72
137	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	1.2	29
138	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5506-5506.	0.8	2
139	Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10-10.	0.8	0
140	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4149-4162.	3.2	61
141	Current Phase II clinical data for ridaforolimus in cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1485-1493.	1.9	6
142	Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 6219-6229.	3.2	53
143	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. <i>Frontiers in Pharmacology</i> , 2013, 4, 35.	1.6	32
144	A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5039-5039.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Common PIK3CA Mutants and a Novel 3' UTR Mutation Are Associated with Increased Sensitivity to Saracatinib. <i>Clinical Cancer Research</i> , 2012, 18, 2704-2714.	3.2	41
146	Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2012, 7, 40-48.	0.5	40
147	ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a β -secretase inhibitor and irinotecan in colorectal cancer. <i>Molecular Oncology</i> , 2012, 6, 370-381.	2.1	32
148	Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3351-3362.	1.9	71
149	Phase II Study of Asparagine-Glycine-Arginine Human Tumor Necrosis Factor \pm , a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2604-2611.	0.8	111
150	Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. <i>European Journal of Cancer</i> , 2010, 46, 198-206.	1.3	50
151	Abstract A38: Members of the noncanonical WNT pathway confer resistance to the MEK 1/2 inhibitor AZD6244 in colorectal cancer cell lines. , 2009, , .		2
152	Abstract A40: MicroRNA expression patterns as potential biomarkers of responsiveness to the MEK1/2 inhibitor, AZD6244, in colorectal cancer cell lines. , 2009, , .		0
153	The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1468-1481.	0.5	188
154	Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1026-1031.	0.5	37
155	Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. <i>Journal of the National Cancer Institute</i> , 2007, 99, 838-846.	3.0	303
156	Endothelial Growth Factor Receptor Inhibition after Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2007, 2, 662.	0.5	1
157	M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum. <i>Journal of Thoracic Oncology</i> , 2007, 2, S167-S168.	0.5	0
158	Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2007, 110, 845-853.	2.0	38
159	Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial. <i>Pancreatology</i> , 2006, 6, 454-463.	0.5	29
160	Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1739-1742.	3.0	232
161	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1133-1141.	3.0	367
162	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6006-6012.	3.2	40